CurrentUnitedHealthcarePolicy CS129.V

Vagus and External Trigeminal Nerve Stimulation

Defines UnitedHealthcare coverage position for implantable vagus nerve stimulators (VNS) and nonimplantable/transcutaneous VNS and external trigeminal nerve stimulation (TNS), including indications considered medically necessary (epilepsy) and those considered unproven/not medically necessary, with applicable procedure and HCPCS/CPT codes and clinical documentation notes. Excludes certain states where separate state-specific policy applies.

Policy Summary

PayerUnitedHealthcare

PolicyVagus and External Trigeminal Nerve Stimulation

Policy CodePolicy CS129.V

Change TypeTemplate and documentation updates

Effective DateDec 1, 2025

Next Review Date

Key ActionSubmit medical records demonstrating medically refractory epilepsy (failure of ≥2 antiepileptic drug trials or intolerable side effects), documentation regarding surgical candidacy or refusal after shared decision making, and history confirming no left/bilateral cervical vagotomy.

SourceLink

POLICY UPDATE CHANGES

04/01/2026 Template Update removed content/language pertaining to the state of Louisiana.

03/01/2026 Updated reference link to reflect the current policy title for Transcranial Magnetic Stimulation for Treating Physical Health Conditions.

12/01/2025 Updated list of Medical Records Documentation Used for Reviews; removed 'quality of life assessment with quantifiable measures of date-to-life besides the occurrence of seizures'.

1Covered Indications (implantable VNS)

2Not medically necessary (tVNS, external TNS)

20+

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

UnitedHealthcare covers implantable vagus nerve stimulation (VNS) for drug‑resistant epilepsy when specified criteria are met (see Coverage Rationale requiring medically refractory seizures with failure of ≥2 antiepileptic drug trials or intolerable side effects, lack of surgical candidacy or refusal after Shared Decision Making, and no history of left or bilateral cervical vagotomy). Transcutaneous/non‑implantable VNS modalities and external/transcutaneous trigeminal nerve stimulation (TNS/eTNS) are classified as unproven and not medically necessary for all indications. The policy notes that it does not apply to certain states with state‑specific policies and is identified as Policy Number CS129.V with an effective date of 2025-12-01.

Quick facts

Medical-Necessity Criteria

Implantable Vagus Nerve Stimulator - Medically Necessary

Covered when ALL of the following are met:

ALL of the following

Medically refractory epileptic seizures with failure of two or more trials of single or combination antiepileptic drug therapy or intolerable side effects of antiepileptic drug therapy
The individual is not a candidate for epilepsy surgery, has failed epilepsy surgery, or refuses epilepsy surgery after Shared Decision Making discussion
No history of left or bilateral cervical vagotomy (FDA-identified contraindication)

ref": "b1_0","title": "Implantable Vagus Nerve Stimulator - Medically Necessary

Coding

Referenced CPT / Procedure CodesCPT

61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.

Referenced HCPCS / DME / Supply CodesHCPCS

A4541	Monthly supplies for use of device coded at E0733
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve.
E0735	Noninvasive vagus nerve stimulator.
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified.
E1399	Durable medical equipment, miscellaneous.
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.

1–10 of 13

1/2

Provider Actions & Documentation

Documentation Required

Clinical documentation to support medical necessity for VNS

Submit medical records demonstrating medically refractory epilepsy — defined as failure of two or more trials of single or combination antiepileptic drug therapy or intolerable side effects of antiepileptic drug therapy. Include documentation that the individual is not a candidate for epilepsy surgery, has failed epilepsy surgery, or has refused epilepsy surgery after a Shared Decision Making discussion. Provide history showing no left or bilateral cervical vagotomy (FDA-identified contraindication).

Evidence of ≥2 antiepileptic drug trials (or documented intolerable side effects)
Documentation of surgical candidacy assessment or documented refusal after Shared Decision Making
Clinical history confirming no left or bilateral cervical vagotomy

Documentation Required

Medical records documentation used for reviews

Medical records submitted for review should follow the policy's list of documentation used for reviews. Note that the December 1, 2025 revision removed the requirement for a “quality of life assessment with quantifiable measures of date‑to‑life besides the occurrence of seizures.” This removal is informational regarding the documentation list.

Background and Evidence Summary

Vagus nerve stimulation (VNS) delivers electrical impulses to the brain via the vagus nerve; implantable systems use a surgically placed generator and stimulating leads around the cervical vagus nerve and may act via multiple proposed pathways (neurotransmitter release, increased cerebral blood flow, EEG desynchronization). Device models include traditional/open‑loop systems with on/off cycles and magnet activation, and closed‑loop/responsive systems that trigger stimulation in response to physiologic changes (e.g., ictal heart‑rate increases). Noninvasive modalities include transcutaneous/auricular or cervical tVNS devices (e.g., handheld gammaCore) and external/transcutaneous trigeminal nerve stimulation (TNS/eTNS) devices that apply surface electrodes to auricular, cervical, forehead, or supraorbital regions to stimulate the targeted nerve branches.

Source	Key point
Panebianco Cochrane review (2015, updated 2022)
VNS appears effective and well tolerated for partial (focal) seizures in included trials but evidence is limited; certainty moderate to low.
Registry and meta-analysis outcomes
Responder rates for VNS increase over time (examples: ~38–63% responders across studies; registry data show ~63% responders at 24–48 months) and seizure freedom rates are low (approx 5–8%).
Diniz et al. (2024)
In battery replacement to cardiac-based VNS, odds ratio for ≥50% seizure reduction 1.79 (95% CI 1.07–2.97); significant effects also for ≥80% reduction (OR 2.06).
References cited
Numerous clinical trials, systematic reviews, guidelines and registry reports cited (e.g., AAN guideline 2013, NICE guidance, multiple RCTs and registry reports through 2025).

Definitions

Shared Decision Making: “A collaborative process in which a provider/clinician and a patient (including caregivers and family) work together to make healthcare decisions… comparing the benefits, harms, and risks of each option and discussing what matters most to the patient (AHRQ, About Shared Decision Making, 2023).”

Note: The definition of Shared Decision Making was updated in the 12/01/2025 revision (text changed; prior version archived).

Revision History

2025-12-01revision

12/01/2025 Updated list of Medical Records Documentation Used for Reviews; removed 'quality of life assessment with quantifiable measures of date-to-life besides the occurrence of seizures'. Also updated definition of 'Shared Decision Making' and supporting information sections; archived previous policy version CS129.U. (is_material: false)

2026-03-01revision

03/01/2026 Updated reference link to reflect the current policy title for Transcranial Magnetic Stimulation for Treating Physical Health Conditions. (is_material: false)

2026-04-01template_update

Scope and Limitations

Scope: This policy defines UnitedHealthcare's coverage position for implantable VNS and for nonimplantable/transcutaneous VNS and external trigeminal nerve stimulation (TNS/eTNS). Implantable VNS is considered medically necessary for drug‑resistant epilepsy when ALL specified clinical criteria are met; implantable VNS is unproven/not medically necessary for all other conditions. Transcutaneous (non‑implantable) VNS and external/transcutaneous TNS devices are specifically listed as unproven and not medically necessary for preventing or treating all indications.

Application limits / excluded states: This Medical Policy does not apply to certain states that have separate state‑specific policies (see list of states with applicable state policies). When federal, state, or contractual benefit requirements differ from this policy, those requirements govern.